Postoperative adjuvant PD-1 immunotherapy survival and body-mass-index dynamics in esophageal cancer: A real-world retrospective study

Table 1 Baseline characteristics, n (%)

Characteristic	Total	Characteristic	Total
Gender		Classification
Male	38 (86.36)	Nonsquamous	4 (9.09)
Female	6 (13.64)	Squamous	40 (90.91)
Median age, year	64.0 (59.09-68.0)	Immunotherapy
Age, year		Sindilizumab	11 (25.0)
≤ 60	12 (27.27)	Karelizumab	1 (2.27)
> 60	32 (72.73)	Tirelizumab	18 (40.91)
T stage		Pabolizumab	1 (2.27)
1b	6 (13.64)	Teraplizumab	10 (22.73)
2	7 (15.91)	Others	3 (6.82)
3	31 (70.45)	Joint plan
N stage		No	3 (6.82)
0	11 (25.0)	CT	29 (65.91)
1	16 (36.36)	RT	2 (4.55)
2	9 (20.45)	RCT	10 (22.73)
3	8 (18.18)	Recurrence
Differentiation		No	35 (79.55)
High	9 (20.45)	Original	2 (4.55)
Median	21 (47.73)	Distant	7 (15.91)
Low	14 (31.82)

CT: Chemotherapy; RT: Radiotherapy; RCT: Concurrent chemoradiotherapy.

Table 2 Univariate and multivariate Cox regression analysis of variables related to progression-free survival

Subgroup	Univariate analysis		Multivariate analysis
	P value	HR (95%CI)	P value	HR (95%CI)
Age, year
< 60		1.00		1.00
≥ 60	0.368	0.57 (0.17-1.95)
T stage
≤ 2		1.00		1.00
> 2	0.494	0.65 (0.19-2.23)
N stage
pN0		1.00		1.00
pN ≥ 1	0.509	0.64 (0.17-2.43)
G
G1		1.00		1.00
G2	0.623	0.06 (0.13-3.47)
G3	0.947	1.06 (0.19-5.58)
TNM
≤ II		1.00		1.00
> II	0.974	0.98 (0.26-3.7)
CPS
< 10		1.00		1.00
≥ 10	0.139	0.31 (0.07-1.46)
Joint plan
CT	0.24	0.26 (0.03-2.44)
RT	0.998	0
RCT	0.653	0.59 (0.06-5.8)
BMI
BMI1	0.113	1.22 (0.95-1.57)
BMI2	0.932	0.99 (0.99-1.26)
BMIdv	0.046	0.74 (0.55-1)	0.04	0.69 (0.49-0.98)
L
L1	0.019	0.23 (0.07-0.79)	0.196	0.31 (0.05-1.84)
L2	0.437	0.63 (0.2-2.01)
N
N1	0.199	1.36 (0.85-2.17)
N2	0.655	0.92 (0.62-1.35)
NLR
NLR1	0.014	1.18 (1.03-1.34)	0.688	1.13 (0.63-2.04)
NLR2	0.378	1.12 (0.87-1.43)
NLRdv	0.100	0.87 (0.73-1.03)
Hb
Hb1	0.741	0.99 (0.95-1.03)
Hb2	0.578	1.01 (0.97-1.06)
Hbdv	0.440	1.02 (0.98-1.06)
WBC
WBC1	0.937	1.02 (0.67-1.55)
WBC2	0.517	0.89 (0.63-1.27)
WBCdv	0.440	0.87 (0.62-1.23)
SII
SII1	0.105	1 (1-1)
SII2	0.937	1 (1-1)
SIIdv	0.246	1 (1-1)
PLT
PLT1	0.332	1 (0.99-1)
PLT2	0.446	1 (0.99-1)
Time	0.027	1.04 (1-1.08)	0.721	0.97 (0.84-1.12)

BMI1: Preoperative body mass index; Hb1: Preoperative hemoglobin; L1: Preoperative lymphocyte count; L1: Preoperative neutrophil count; Plt1: Preoperative platelet count; WBC1: Preoperative white blood cell count; BMI2: Body-mass-index at start of first immunotherapy; Hb2: Hemoglobin at the start of the first immunotherapy; L2: Lymphocyte count at the start of the first immunotherapy session; N2: Neutrophil count at the start of the first immunotherapy session; Plt2: Platelet count at start of first immunotherapy; WBC2: White blood cell count at the start of the first immunotherapy session; NLR: Ratio of neutrophils to lymphocytes; SII: Systemic immunoinflammatory index; dv: Difference between the index at the beginning of the first immunotherapy minus the index before surgery; Time: Time interval between surgery and start of first immunotherapy.

Table 3 Adverse reactions during immunotherapy, n (%)

AE	Total (n = 44), AE (n = 12, 27.3%)
	Grade 1	Grade 2	Grade 3	Grade 4
Tiredness	3 (6.82)	1 (2.27)	/	/
Nausea	/	2 (4.55)	/	/
Hyperpigmentation	/	1 (2.27)	/	/
Fever	/	1 (2.27)	/	/
Hypothyroidism	/	1 (2.27)	/	/
Neutropenia	/	1 (2.27)	/	2 (4.55)

AE: Adverse event.